Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PHASE II STUDY Evaluating the Toxicity and Activity of the Combination Lapatinib + Capecitabine in Elderly Patients Aged 70 and Over With Metastatic Breast Cancer Over Expressing HER2

NCT01262469 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT01262469
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01262469 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PHASE II STUDY Evaluating the Toxicity and Activity of the Combination Lapatinib + Capecitabine in Elderly Patients Aged 70 and Over With Metastatic Breast Cancer Over Expressing HER2
Lead sponsor
UNICANCER
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2009
Completion date
November 30, 2013
Enrollment
4 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

70 years old patients and over, after one line of chemotherapy with trastuzumab, metastatic breast cancer